Stephanie Christopher’s Post

We are thrilled to announce that Chief Scientific Officer, ARMELLE PINDON, PhD, and Board Member, Alexis Elder, will both be panelists at the 2024 World Orphan Drug Congress USA in Boston, MA on April 24-25. "The World Orphan Drug Congress brings together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers. The conference is a place to meet and brainstorm ways to advance orphan drug development and improve access to life-saving therapies." -WODC Website We look forward to sharing more about all the wonderful discussions! #WorldOrphanDrugCongress #WODC #VCPdisease #raredisease #CureVCPDisease

🎙️ “The progress the industry was able to make was really unprecedented.” ⚕️ Senior Director of Advocacy & Strategic Alliances for PhRMA, Christine Harhaj, joins us to discuss the growth of the pharmaceutical industry since COVID-19. Listen now at www.thepulsehealthcast.com!

Today, 29 February 2024, is Rare Disease Day. Avance Clinical is proud to have completed over 60 clinical trials for rare diseases in the past 5 years. In late April, the North American team will attend the World Orphan Drug Congress USA in Boston. The World Orphan Drug Congress brings together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers. The conference is a place to meet and brainstorm ways to advance orphan drug development and improve access to life-saving therapies. Book a meeting with our team of clinical trial experts 👇 https://lnkd.in/eQ5s_fw #AvanceClinical #CRO #clinicaltrials #drugdevelopment #raredisease #worldorphandrugcongress #Boston #USA #Australia #RareDiseaseDay #awareness #biotech #clinicalresearch

Last week, Adam Feuerstein of STAT+ highlighted the complex relationships between patient organizations and pharmaceutical companies. This story emphasizes the need for industry transparency, the independence of advocacy organizations, and the respect for patients contributing to research. Rx4good's Chief Patient Advocate and SVP, Heidi Schultz Adams, shares her insights on our blog. Read more here: https://shorturl.at/9USy7 and sign up for our Good4Patients newsletter to keep up with the latest.

Putting Patients at the Heart of Drug Development We're thrilled to announce the first-panel discussion at the prestigious Prix Galien UK 2024 awards ceremony titled "No Decision for Me Without Me: Putting Patients at the Heart of Drug Development." At Galien, we firmly believe that patients must have a voice in the process of developing new medicines that impact their lives. This panel brings together renowned experts spanning patient advocacy, regulatory bodies, and pharmaceutical R&D to explore how we can truly embed the patient perspective throughout the drug development journey. Our esteemed panelists include: Panel Chair: Dr. Mel Walker Strategic Advisor and Managing Director at BioPharma Futures Panelists: 1. Robyn Bent, Director of CDER's Patient-Focused Drug Development Program at FDA 2. Dr. Sarah Gheuens, Chief Medical Officer and Head of R&D at Agios Pharmaceuticals 3. Dr. Maria Mavris, Patient Liaison at European Medicines Agency 4. Elizabeth Vroom, Co-founder and Chair of World Duchenne Organization Join us as we dive into best practices for meaningful patient engagement, discuss regulatory initiatives promoting patient-centricity, and explore innovative ways to amplify the patient voice from drug discovery through commercialization. The path to developing transformative medicines lies in listening to and co-creating solutions with those most impacted. This panel reflects our commitment to that ideal. Follow us at The Galien Foundation for live updates and insights from this must-attend session. #PrixGalienUK2024 #PatientCentricInnovation

This years Forum, organised by The Galien Foundation, promises some really interesting and topical discussions. We are increasingly working with companies who are placing greater emphasis on the patient voice in R&D and it will be good to hear regulatory, industry and patient perspectives on the panel chaired by Mel Walker #Patientengagenent #Pharmaceuticals

Navigating Rare Disease Drug Development: FDA's New Paradigm Published by: The #FDA in #UnitedStates. December 21, 2023 Key Points Learnings: 🔺 Streamlined Development: Guides drug developers in creating efficient programs for rare disease treatments. 🔺 Strategic Focus: Addresses common challenges in rare disease drug development. 🔺 Regulatory Insight: Offers comprehensive regulatory perspectives crucial for successful drug approval. 🔺 Innovation Encouragement: Aims to foster innovative approaches in tackling rare diseases. 🔺 Stakeholder Collaboration: Stresses the importance of collaborative efforts between industry and regulators. The recent FDA guidance document marks a significant stride in the pharmaceutical industry's journey towards better addressing rare diseases. For more information - https://lnkd.in/g8XC3kdb #FDA PharmOut #RareDiseaseInnovation #DrugDevelopment #BiologicalProductGuidance #HealthcareAdvancement

Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen joined Proactive's Stephen Gunnion with details of the positive feedback from the US Food and Drug Administration (FDA) regarding its Phase III clinical trial for its lead asset, bexmarilimab (BEXMAB). Jalkanen shared that the FDA’s guidance will accelerate trials, potentially bringing new treatments to the market sooner. He explained, “We went with a humble attitude to the FDA, proposing a Phase III trial for relapsed refractory MDS. The big news is that the FDA recommended going directly into a frontline MDS study, opening up a much larger market sooner than anticipated.” This acceleration not only speeds up the process but also targets a larger patient population without significantly increasing trial costs. Jalkanen also highlighted the importance of the Frontrunner program, which promises to bring treatments to patients faster in areas of high unmet... Watch at #Proactive #ProactiveInvestors http://ow.ly/qi80105AfnJ

In February of 2023, the Pharmaceutical Accountability Foundation brought a lawsuit against AbbVie, on the grounds that the company overcharged the Dutch healthcare system by as much as €1.2 billion through excessive pricing on its blockbuster rheumatoid arthritis medicine, #Humira. Want to know more about why we are taking AbbVie to court in the Netherlands? Watch our explainer on YouTube: https://lnkd.in/eawUA25S In februari 2023 spande de Stichting Farma ter Verantwoording (FtV) een rechtszaak aan tegen AbbVie. AbbVie heeft het Nederlandse zorgstelsel naar schatting € 1,2 miljard te veel in rekening gebracht met de verkoop van haar reumatoïde artritis medicijn, #Humira.

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!